Xuming Dai

Xuming Dai

Auto-generated profile, based on publicly available information

Xuming Dai

Division of Cardiology, University of North Carolina, Chapel Hill, NC 27599-7075, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Blood
Verified
Journal Article
Closed access
PDF file
XDXu-Ming Dai
Xu-Ming Dai
GRGregory R. Ryan
Gregory R. Ryan
AHAndrew J. Hapel
Andrew J. Hapel
MDMelissa G. Dominguez
Melissa G. Dominguez
RRRobert G. Russell
Robert G. Russell
ESE. Richard Stanley
E. Richard Stanley
The effects of colony-stimulating factor 1 (CSF-1), the primary regulator of mononuclear phagocyte production, are thought to be mediated by the CSF-1 receptor (CSF-1R), encoded by the c-fms proto-oncogene. To investigate the in vivo specificity of CSF-1 for the CSF-1R, the mouse Csf1r gene was inactivated. The phenotype ofCsf1−/Csf1r− mice closely resembled the phenotype of CSF-1-nullizygous(Csf1op/Csf1op) mice, including the osteopetrotic, hematopoietic, tissue macrophage, and reproductive phenotypes. Compared with their wild-type littermates, splenic erythroid burst-forming unit and high-proliferative potential colony-forming cell levels in bothCsf1op/Csf1op andCsf1−/Csf1r− mice were significantly elevated, consistent with a negative regulatory role of CSF-1 in erythropoiesis and the maintenance of primitive hematopoietic progenitor cells. The circulating CSF-1 concentration inCsf1r−/Csf1r− mice was elevated 20-fold, in agreement with the previously reported clearance of circulating CSF-1 by CSF-1R–mediated endocytosis and intracellular destruction. Despite their overall similarity, several phenotypic characteristics of theCsf1r−/Csf1r− mice were more severe than those of theCsf1op/Csf1op mice. The results indicate that all of the effects of CSF-1 are mediated via the CSF-1R, but that subtle effects of the CSF-1R could result from its CSF-1–independent activation.

29 January 2006 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
FGFlorent Ginhoux
Florent Ginhoux
FTFrank Tacke
Frank Tacke
VAVeronique Angeli
Veronique Angeli
MBMilena Bogunovic
Milena Bogunovic
MLMartine Loubeau
Martine Loubeau
MMMiriam Merad
Miriam Merad

1 July 2012 in Developmental Biology
Verified
Journal Article
Closed access
SNSayan Nandi
Sayan Nandi
SGSolen Gokhan
Solen Gokhan
XDXu-Ming Dai
Xu-Ming Dai
SWSuwen Wei
Suwen Wei
GEGrigori Enikolopov
Grigori Enikolopov
ESE. Richard Stanley
E. Richard Stanley

1 July 2001 in Blood
Verified
Journal Article
Open access
GRGregory R. Ryan
Gregory R. Ryan
XDXu-Ming Dai
Xu-Ming Dai
MDMelissa G. Dominguez
Melissa G. Dominguez
WTWei Tong
Wei Tong
FCFenchi Chuan
Fenchi Chuan
ESE. Richard Stanley
E. Richard Stanley
Colony-stimulating factor 1 (CSF-1) regulates the survival, proliferation, and differentiation of mononuclear phagocytes. It is expressed as a secreted glycoprotein or proteoglycan found in the circulation or as a biologically active cell-surface glycoprotein. To investigate tissue CSF-1 regulation, CSF-1–nullCsf1op/Csf1opmice expressing transgenes encoding the full-length membrane-spanning CSF-1 precursor driven by 3.13 kilobases of the mouse CSF-1 promoter and first intron were characterized. Transgene expression corrected the gross osteopetrotic, neurologic, weight, tooth, and reproductive defects ofCsf1op/Csf1opmice. Detailed analysis of one transgenic line revealed that circulating CSF-1, tissue macrophage numbers, hematopoietic tissue cellularity, and hematopoietic parameters were normalized. Tissue CSF-1 levels were normal except for elevations in 4 secretory tissues. Skin fibroblasts from the transgenic mice secreted normal amounts of CSF-1 but also expressed some cell-surface CSF-1. Also, lacZ driven by the same promoter/first intron revealed β-galactosidase expression in hematopoietic, reproductive, and other tissue locations proximal to CSF-1 cellular targets, consistent with local regulation by CSF-1 at these sites. These studies indicate that the 3.13-kilobase promoter/first intron confers essentially normal CSF-1 expression. They also pinpoint new cellular sites of CSF-1 expression, including ovarian granulosa cells, mammary ductal epithelium, testicular Leydig cells, serous acinar cells of salivary gland, Paneth cells of the small intestine, as well as local sites in several other tissues.

1 January 2016 in World Journal of Cardiology
Verified
Journal Article
Open access
XDXuming Dai
Xuming Dai
SWSzymon Wiernek
Szymon Wiernek
JEJames P Evans
James P Evans
MRMarschall S Runge
Marschall S Runge
Atherosclerotic coronary artery disease (CAD) comprises a broad spectrum of clinical entities that include asymptomatic subclinical atherosclerosis and its clinical complications, such as angina pectoris, myocardial infarction (MI) and sudden cardiac death. CAD continues to be the leading cause of death in industrialized society. The long-recognized familial clustering of CAD suggests that genetics plays a central role in its development, with the heritability of CAD and MI estimated at approximately 50% to 60%. Understanding the genetic architecture of CAD and MI has proven to be difficult and costly due to the heterogeneity of clinical CAD and the underlying multi-decade complex pathophysiological processes that involve both genetic and environmental interactions. This review describes the clinical heterogeneity of CAD and MI to clarify the disease spectrum in genetic studies, provides a brief overview of the historical understanding and estimation of the heritability of CAD and MI, recounts major gene discoveries of potential causal mutations in familial CAD and MI, summarizes CAD and MI-associated genetic variants identified using candidate gene approaches and genome-wide association studies (GWAS), and summarizes the current status of the construction and validations of genetic risk scores for lifetime risk prediction and guidance for preventive strategies. Potential protective genetic factors against the development of CAD and MI are also discussed. Finally, GWAS have identified multiple genetic factors associated with an increased risk of in-stent restenosis following stent placement for obstructive CAD. This review will also address genetic factors associated with in-stent restenosis, which may ultimately guide clinical decision-making regarding revascularization strategies for patients with CAD and MI.

1 February 2004 in Blood
Verified
Journal Article
Open access
PDF file
XDXu-Ming Dai
Xu-Ming Dai
XZXiao-Hua Zong
Xiao-Hua Zong
VSVonetta Sylvestre
Vonetta Sylvestre
ESE. Richard Stanley
E. Richard Stanley
The primary macrophage growth factor, colony-stimulating factor 1 (CSF-1), is expressed as a secreted glycoprotein or proteoglycan found in the circulation or as a biologically active cell surface glycoprotein (csCSF-1). To investigate the in vivo roles of csCSF-1, we created mice that exclusively express csCSF-1, in a normal tissue-specific and developmental manner, by transgenic expression of csCSF-1 in the CSF-1-deficient osteopetrotic (Csf1op/Csf1op) background. The gross defects of Csf1op/Csf1op mice, including growth retardation, failure of tooth eruption, and abnormal male and female reproductive functions were corrected. Macrophage densities in perinatal liver, bladder, sublinguinal salivary gland, kidney cortex, dermis, and synovial membrane were completely restored, whereas only partial or no restoration was achieved in adult liver, adrenal gland, kidney medulla, spleen, peritoneal cavity, and intestine. Residual osteopetrosis, significantly delayed trabecular bone resorption in the subepiphyseal region of the long bone, and incomplete correction of the hematologic abnormalities in the peripheral blood, bone marrow, and spleens of CSF-1-deficient mice were also found in mice exclusively expressing csCSF-1. These data suggest that although csCSF-1 alone is able to normalize several aspects of development in Csf1op/Csf1op mice, it cannot fully restore in vivo CSF-1 function, which requires the presence of the secreted glycoprotein and/or proteoglycan forms. (Blood. 2004;103:1114-1123)